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SUMMARY 33 
The commonest causes of chronic liver disease are excess alcohol intake, viral 34 
hepatitis or non-alcoholic fatty liver disease, with the clinical spectrum ranging 35 
in severity from hepatic inflammation through cirrhosis to liver failure or 36 
hepatocellular carcinoma. The hepatocellular carcinoma genome exhibits diverse 37 
mutational signatures, resulting in recurrent mutations across >20-30 cancer 38 
genes1–7. Stem cells from normal livers have low mutation burden and limited 39 
diversity of signatures8, suggesting that the complexity of hepatocellular 40 
carcinoma arises during progression to chronic liver disease and subsequent 41 
malignant transformation. We sequenced whole genomes of 482 42 
microdissections of 100-500 hepatocytes from 5 normal and 9 cirrhotic livers. 43 
Compared to normal liver, cirrhotic liver had higher mutation burden. Although 44 
rare in normal hepatocytes, structural variants, including chromothripsis, were 45 
prominent in cirrhosis. Driver mutations, both point mutations and structural 46 
variants, affected 1-5% clones. Clonal expansions millimetres in diameter 47 
occurred in cirrhosis, sequestered by bands of fibrosis engirdling regenerative 48 
nodules. Some mutational signatures were universal and equally active in both 49 
non-malignant hepatocytes and HCC; some were substantially more active in 50 
HCC than chronic liver disease; and others, arising from exogenous exposures, 51 
were present in a subset of patients. Up to 10-fold within-patient variation in 52 
activity of exogenous signatures existed between adjacent cirrhotic nodules, 53 
arising from clone-specific and microenvironmental forces. Synchronous 54 
hepatocellular carcinomas exhibited the same mutational signatures as 55 
background cirrhotic liver, but with higher burden. Somatic mutations chronicle 56 
the exposures, toxicity, regeneration and clonal structure of liver tissue as it 57 
progresses from health to disease. 58 
    59 
MAIN TEXT 60 
Identifying somatic mutations in non-malignant tissue requires approaches to 61 
overcome its polyclonality, such as single cell sequencing9, cultures of single 62 
cells8,10 or microbiopsy sequencing11. The latter relies on local cell division with 63 
limited migration leading to a clonal patchwork, a known property of 64 
hepatocytes12. We generated whole genome sequences from 482 laser-capture 65 
microdissections of 100-500 hepatocytes (Extended Figure 1A) across 14 66 
patients: 5 normal controls; 4 with cirrhosis from alcohol-related liver disease 67 
(ARLD) and 5 with cirrhosis from non-alcoholic fatty liver disease (NAFLD) 68 
(Supplementary Tables 1-2, Extended Figures 4-6). Samples of normal liver 69 
were acquired from hepatic resections of colorectal cancer metastases; samples 70 
of cirrhotic liver from patients transplanted for synchronous but distant 71 
hepatocellular carcinoma (HCC).  72 
 73 
To evaluate sensitivity and specificity, we generated independent libraries and 74 
sequencing data from different sections of the same biopsy, microdissecting the 75 
same x,y-region from adjacent z-stacks, separated by ~20m. Concordance was 76 
high between variants called in adjacent sections, but not distant pairs, 77 
suggesting that specificity of mutation calls was high (Extended Figure 1B), and 78 
sensitivity across patients was 50-95%, dependent on coverage and clonality 79 
(Extended Figure 1C-F). As a further check on specificity, deep targeted 80 
sequencing of cancer genes in the same library as 96 whole-genome samples 81 
confirmed 16 of 17 mutations originally called. In keeping with polyploidy as a 82 
late differentiation stage in liver13, 20-25% of mature hepatocytes in 83 
microdissected samples were multinuclear (Extended Figure 1G). We therefore 84 
deployed copy number algorithms with expected ploidy of 4, and report 85 
mutation burdens per diploid genome, rather than per cell. 86 
 87 
We observed considerable heterogeneity in burden of somatic substitutions both 88 
between and within patients (Figure 1A; Supplementary Tables 3-4). Using 89 
mixed effects models, microdissections from cirrhotic livers had, on average, 90 
1251 (CI95% 233-2268; p=0.02) extra substitutions per diploid genome 91 
compared to normal livers, independent of age. In accordance with published 92 
values8, the estimated rate of mutation accumulation was 33/year/diploid 93 
genome, albeit with wide confidence intervals (CI95% -17–84; p=0.18) and 94 
moderate variation between individuals (estimated between-individual SD, 95 
13/year). Indels showed the same heterogeneity between and within individuals 96 
as substitutions (Figure 1B). 97 
 98 
Structural variants and copy number alterations occurred in moderate numbers 99 
across all 9 patients with liver cirrhosis, despite being rare in normal liver 100 
(Figure 1C, Extended Figure 2, Supplementary Tables 3-4). Occasional whole 101 
chromosome or arm-level aneuploidy occurred, as well as focal events, including 102 
deletions, tandem duplications and unbalanced translocations (Extended Figure 103 
2). We found 5 separate clusters of SVs, across 3 patients, with patterns 104 
indicative of chromothripsis14 (Figures 1D-F, Extended Figure 2). 105 
Chromothripsis, in which multiple rearrangements occur in a single catastrophic 106 
mitosis14, is a major mutational process in cancers, occurring in ~5% of HCCs15, 107 
but is rare in normal somatic cells. To see 1-2% of clones in chronic liver disease 108 
with chromothripsis suggests that sustained toxicity and regeneration 109 
substantially increases mitotic stress in hepatocytes.    110 
 111 
We screened for driver mutations among coding regions, 5’-UTRs, 3’-UTRs and 112 
promoters (Supplementary Tables 5-8). No elements were significant after 113 
genome-wide multiple hypothesis correction, so we focused on the 30 most 114 
prevalent HCC genes1–5. These carried 22 non-synonymous variants, seen in both 115 
normal and cirrhotic samples, including inactivating mutations in the tumour 116 
suppressor genes ACVR2A, ARID2, ARID1A and TSC2 (Extended Figure 3A). With 117 
hypothesis testing restricted to these 30 genes, ALB (q=0.001) and ACVR2A 118 
(q=0.001) were significant. Recurrence in ALB (albumin) likely reflects a 119 
mutational process in which indels preferentially occur in highly expressed 120 
genes, as reported in HCCs5,16 (Extended Figure 3B-C). Assuming no negative 121 
selection, we can use the ratio of non-synonymous to synonymous substitutions 122 
for the 30 HCC genes to estimate the number of driver substitutions among 123 
them17 – this gives a 95% confidence interval of 0.0–13.2 drivers in total across 124 
482 microdissections (<3%). Among copy number aberrations of potential 125 
significance1,2,18 (Supplementary Table 9), we found instances of chromosome 126 
22 loss, 8q gain and 8p loss. Two focal deletions in different patients spanned 127 
ACVR2A (Extended Figure 2C,E). We also found a reciprocal inversion that 128 
deleted CDKN2A (Extended Figure 2F), the most common focal deletion in HCC, 129 
and a deletion affecting ARID5A.  130 
 131 
We reconstructed phylogenetic trees19, layering them onto the specimen’s 132 
histology. Samples from the healthy controls showed the highly polyclonal 133 
nature of normal liver, with little genetic relatedness among even closely located 134 
microdissections (Figure 2A-D, Extended Figure 4). Samples from patients 135 
with chronic liver disease showed more complex clonal structure, from which 136 
three general inferences can be drawn (Figure 2E-P, Extended Figures 5-6). 137 
First, we found no sharing of mutations between adjacent liver nodules 138 
separated by fibrotic bands. This suggests that the connective tissue laid down 139 
during cycles of damage and regeneration sequesters clones from early stages of 140 
the disease process. Second, some cirrhotic nodules were monoclonally derived 141 
(Figure 2J,N, for example), while others were oligoclonal (Figure 2F), with 142 
shared mutations often extending across microdissections millimetres apart. 143 
Third, branching structures in phylogenies point to subclonal diversification 144 
within nodules. Within such a clone, the proportion of shared, clonal mutations 145 
on the trunk relative to those on the subclonal branches gives an estimate in 146 
molecular time of when the most recent common ancestor of the clone emerged. 147 
In some patients (for example, Figure 2I-J), the common ancestor of individual 148 
nodules emerged relatively early in molecular time, while in others (Figure 2M-149 
N), the common ancestor appeared much more recently. Since the majority of 150 
liver cells do not have driver mutations, the size and rapidity of clonal 151 
expansions observed here evince the considerable in-built capacity of 152 
hepatocytes to regenerate in response to liver damage.  153 
 154 
A major debate in modelling cancer development is whether cancers need higher 155 
mutation rates in order to acquire sufficient drivers. We compared mutation 156 
burden in cirrhotic liver to synchronous, clonally unrelated HCCs from 7 157 
patients. Synchronous HCCs carried, on average, 4600 more mutations than 158 
matched cirrhotic liver (CI95% 3600-5500; p<10-18 LME models; Figure 3A). This 159 
argues that mutation rates increase during malignant transformation, either 160 
through cancer-specific mutational processes or through greater activity in 161 
cancers of widespread mutational processes. 162 
 163 
To assess what mutational processes are active in cirrhosis, we extracted 164 
mutational signatures across our 482 microdissections, the 7 synchronous HCCs 165 
and 54 HCC genomes from TCGA1, using two independent algorithms (Figure 166 
3B-E, Extended Figures 7-8). Three major groups of mutational signatures 167 
emerged: those ubiquitous and similarly active across cirrhosis and HCC; those 168 
quiet in cirrhosis but universally more active in HCC; and those contributing to 169 
some patients but not others, including signatures arising from exogenous 170 
exposures. 171 
 172 
In normal and cirrhotic liver, ubiquitous mutational signatures (5 and Sig.A) 173 
were prevalent across clones, typically accounting for >75% of mutations in 174 
combination. Signature 5 is widespread across cancers, including HCCs2,4,20, and 175 
accumulates linearly with age, suggesting it arises from endogenous mutational 176 
processes. Sig.A is the dominant cause of mutations in normal blood stem 177 
cells10,21 and leukaemias21, suggesting it too arises endogenously. In HCCs, 178 
although Sig.A accounted for a lower proportion of mutations than in normal or 179 
cirrhotic liver, the absolute numbers of mutations attributed to Sig.A were 180 
comparable (Difference between cancer and non-cancer, 60 mutations; CI95% -181 
80-200; p=0.4; Figure 3F, Supplementary Table 10). This suggests that it is 182 
active in hepatocytes throughout life, but is outstripped in HCC by mutational 183 
processes emerging during malignant transformation. 184 
 185 
A second group of mutational signatures comprises processes that are relatively 186 
quiet in cirrhotic liver but universally more active in HCC (signatures 1, 12, 16, 187 
40 and a novel signature, D; Supplementary Table 10). One of these, signature 188 
16, consists of T>C mutations in ApT context and has a known transcriptional 189 
strand bias, with both preferential repair of damaged adenines on transcribed 190 
strands and increased damage on non-transcribed strands22. Although this 191 
signature is more active in HCCs, we do see its characteristic transcriptional 192 
strand bias in cirrhotic liver (Extended Figure 9A). Signature 1, caused by 193 
spontaneous deamination of methylated cytosine to thymine, is also much more 194 
active in HCC than non-malignant liver. The acceleration and universality of 195 
these signatures in HCC suggests they reflect inbuilt DNA damage and repair 196 
processes in hepatocytes that are unmasked during malignant transformation. 197 
 198 
The third group of mutational processes represents signatures seen sporadically 199 
across the cohort, many of which are due to exogenous exposures. One, signature 200 
4, is found in lung cancers from smokers20 and also HCCs, albeit with a less clear-201 
cut relationship to tobacco2.  Of our 14 patients, 4 had >10% of microdissections 202 
with >5% of mutations attributed to signature 4, showing the expected 203 
transcriptional strand bias on guanines (Extended Figure 9B). Not only did 204 
signature 4 show considerable patient-to-patient heterogeneity, there was also 205 
unexpectedly high clone-to-clone and nodule-to-nodule variability within 206 
individual livers. In one patient, for example, about half the clones we sequenced 207 
had 2000-4000 mutations, whereas the other half had 8000-12000, driven by 208 
presence or absence of signature 4 (Figure 4A).  209 
 210 
This within-patient regional variability extended to other exogenous exposures. 211 
In one patient, 20-35% of mutations derived from signature 22 (Figure 4B; 212 
Extended Figure 9C), characteristic of exposure to aristolochic acid23. This 213 
patient grew up in Poland, holidaying in Balkan states where aristolochic acid 214 
exposure is pervasive24. In a different patient, a subset of microdissections had 215 
10-20% mutations attributable to signature 24 (Figure 4C), associated with 216 
aflatoxin-B1 exposure5. Biomarkers of exposure to aflatoxin-B1, produced by 217 
Aspergillus moulds contaminating crops, are prevalent in arable farmers25, the 218 
occupation of our patient. In both patients, these carcinogens showed striking 219 
variability in mutational activity over short distances, generating few mutations 220 
in some clones and hundreds to thousands in others – such striking regional 221 
variation in activity of exogenous signatures is both unexpected and 222 
unexplained.  223 
 224 
In one patient, we found a large clone that carried >2000 mutations attributed to 225 
signature 9 (Figure 4D), caused by off-target somatic hypermutation in B 226 
lymphocytes20. A clonotypic IGH rearrangement was evident, consistent with a 227 
single B lymphocyte subclonally diversifying as it expanded in the liver 228 
(Extended Figure 10). Signature 9 was only present on the ancestral trunk, 229 
whereas signatures in the subclones, acquired in the liver, distributed similarly 230 
to hepatocytes, suggesting the hepatic microenvironment shaped the on-going 231 
mutational processes in the lymphocytes.  232 
 233 
In conclusion, then, non-malignant liver has considerably lower proportions of 234 
clones (<5%) with driver point mutations or structural variants than oesophagus 235 
or skin11,26,27, and those present were seen in both normal and cirrhotic liver.  236 
They did not drive large clonal expansions, being restricted by fibrosis, and were 237 
not shared with the distant synchronous HCCs, suggesting that the increased 238 
cancer risk seen in chronic liver disease arises from a myriad of clones 239 
competing independently to acquire sufficient driver mutations. TERT promoter 240 
mutations are likely to be key events in this progression as they are seen in 241 
dysplastic hepatic nodules18,28, but we did not identify any in cirrhotic or normal 242 
liver. The low proportion of clones with drivers observed here and in exome 243 
studies performed elsewhere29,30 means that much larger sample sizes will be 244 
needed to comprehensively map how driver mutations accumulate in the 245 
progression from normal liver through regenerative and dysplastic nodules to 246 
HCC. 247 
 248 
These data reveal the genomic consequences of chronic liver disease – increased 249 
mutation rates; complex structural variation including chromothripsis; 250 
aneuploidies; low burden of mutations targeting known HCC genes. Genomically, 251 
one middle-aged, healthy liver looks much like any other: a community of small, 252 
tightly packed clones, each comprising a few hundred cells, containing ~1000-253 
1500 mutations, painted from a limited palette of signatures. Unhealthy livers 254 
diverge from this norm: large dynasties of clones, sequestered by impassable 255 
bands of fibrosis, their palette of signatures more variable, more vigorous, more 256 
regionally variegated.  257 
 258 
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FIGURE LEGENDS 383 
 384 
Figure 1: Mutational burden observed in non-cancerous hepatocytes.  385 
(A) Burden of SNVs corrected by sensitivity of mutation detection. Each boxplot 386 
represents a patient (n=14 patients; 482 microdissections), each dot represents 387 
one laser-capture microdissected sample. The grey-to-black intensity of the 388 
points reflects the median variant allele fraction (vaf) of mutations in each 389 
microdissection. Boxes in the box-and-whisker plots indicate median and 390 
interquartile range; whiskers denote range. 391 
(B) Burden of insertion-deletion (INDEL) variants (n=14 patients; 482 392 
microdissections).  393 
(C) Burden of copy number variants (CNVs) and structural variants (SVs), 394 
represented as number of unique events per patient. 395 
(D) Chromothripsis involving chromosomes 16 and 21 observed in patient 396 
PD37111. Black points represent corrected read-depth along the chromosome. 397 
Lines and arcs represent structural variants, coloured by orientation of joined 398 
ends (purple, tail-to-tail inverted; orange, head-to-head inverted; pale blue, 399 
tandem duplication-type orientation; pale green, deletion-type orientation). 400 
(E) Chromothripsis involving chromosomes 1 and 3 observed in patient 401 
PD37105. 402 
(F) Chromothripsis involving chromosomes 2, 5 and 6 observed in patient 403 
PD37105 (in a separate clone to panel E). 404 
 405 
Figure 2: Phylogenetic reconstruction of hepatocyte clones. 406 
(A) Phylogenetic tree constructed from clustering of mutations across 407 
microdissected samples in a normal patient (PD36715). Lengths of branches (x 408 
axis) indicate numbers of mutations assigned to that branch. Solid lines: nesting 409 
is in accordance with the pigeon-hole principle. Dashed lines: nesting is in 410 
accordance with the pigeon-hole principle assuming hepatocytes represent 70% 411 
of cells. Dotted lines: nesting is only based on clustering, assigning a clone as 412 
nested if variant allele fractions of constituent microdissections are lower than 413 
those in the parental clone.  414 
(B) Representation of branches from the phylogenetic tree in panel A according 415 
to their physical coordinates, overlaid onto an H+E stained section. Black points 416 
represent branches of the tree sharing no mutations with any other samples; 417 
coloured points represent branches with shared clonal relationships (n=26 418 
microdissections).  419 
(C, D) A second normal liver sample (PD36713; n=30 microdissections).   420 
(E, F) Patient with ARLD (PD37105; n=31 microdissections) 421 
(G, H) Patient with ARLD (PD37110; n=22 microdissections) 422 
(I, J) Patient with NAFLD (PD37114; n=41 microdissections) 423 
(K, L) Patient with NAFLD (PD37115; n=34 microdissections) 424 
(M, N) Patient with NAFLD (PD37116; 43 microdissections) 425 
(O, P) Patient with NAFLD (PD37118; 26 micordissections) 426 
 427 
Figure 3: Mutational signatures in normal liver, cirrhotic liver and HCC.  428 
(A) Number of somatic substitutions (SNVs; sensitivity-corrected for non-429 
cancerous samples) and insertion-deletion events (INDELs) in each non-cancer 430 
microdissection sample (blue points) and associated synchronous HCC (red 431 
diamonds).  432 
(B) Stacked bar blot showing estimated proportional contributions of each 433 
mutational signature to each phylogenetically defined cluster of somatic 434 
substitutions. Data generated using a Bayesian hierarchical Dirichlet process. 435 
(C) Stacked bar blot showing proportional contributions of signatures in patients 436 
with ARLD.  437 
(D) Stacked bar blot showing estimated proportional contributions of signatures 438 
in patients with NAFLD.  439 
(E) Stacked bar blot showing estimated proportional contributions of signatures 440 
to 54 cases of HCC from TCGA1.  441 
(F) Number of SNVs attributed to prevalent mutation signatures in each non-442 
cancer microdissection sample (blue circles) and synchronous HCCs (red 443 
diamonds). Contributions for the TCGA samples are shown on the right. The y-444 
axis is on a logarithmic scale. 445 
 446 
Figure 4: The liver as a witness for mutagenic insults occurring throughout 447 
life. 448 
(A) Left panel: Phylogenetic tree of clones in patient PD37111, with each branch 449 
coloured by the proportion of mutations in that branch assigned to the different 450 
mutational signatures.  451 
Middle panel: Overlay of the clones represented in (A) onto an H+E stained liver 452 
section of patient PD37111 (n=39 microdissections). Colouring of clones is 453 
according to the proportion of mutations attributed to Sig. 4, linked to tobacco 454 
exposure (blue: low activity of Sig. 4, red: high activity of Sig. 4).  455 
Right panel: Representative mutation spectrum for samples with low (top) or 456 
high (bottom) burden of Sig. 4. The six substitution types are labelled across the 457 
top. Within each substitution type, the contribution from the trinucleotide 458 
context are shown as 16 bars. The 16 bars are divided into four sets of four bars, 459 
grouped by whether an A, C, G or T respectively is 5’ to the mutated base, and 460 
within each group of four by whether A, C, G or T is 3’ to the mutated base. 461 
(B) Overlay of mutational signatures onto phylogenetic tree of clones in patient 462 
PD37107 (n=41 microdissections). Colouring of clones in the middle panel is 463 
according to Sig. 22, linked to the aristolochic acid carcinogen.  464 
(C) Overlay of mutational signatures onto phylogenetic tree of clones in patient 465 
PD36714 (n=35 microdissections). Colouring of clones in middle panel is 466 
according to Sig. 24, linked to the carcinogen aflatoxin-B1.  467 
(D) Overlay of mutational signatures onto phylogenetic tree of clones in patient 468 
PD37113 (n=37 microdissections). Cluster 10 has many mutations attributed to 469 
Sig. 9, linked to the somatic hypermutation process in B lymphocytes.  470 
  471 
EXTENDED FIGURE LEGENDS 472 
 473 
Extended Figure 1: Sensitivity analysis of SNV calls. 474 
(A) Overview schematic of the experimental and analytical approach.  475 
(B) Examples of the variant allele fractions (VAFs) of variants from unrelated 476 
(top) and related (bottom) microdissection sample pairs from four donors (left 477 
to right). X-axis represents the VAF of sample 1 from each pair; Y-axis represents 478 
the VAF of sample 2. Each dot represents one variant. Red: variants called in both 479 
samples, yellow: variants called in sample 1, blue: variants called in sample 2. 480 
(C) Histogram of sensitivities calculated for each sample pair. 481 
(D) Heatmap of modelled sensitivity at different values of VAF and coverage. 482 
Overlaid dots represent sample pairs used to fit model.  483 
(E) Relationship of VAF, sensitivity and coverage according to fitted model of 484 
sensitivity. Overlaid dots represent sample pairs used to fit model.  485 
(F) Comparison of calculated (x-axis) and fitted (y-axis) sensitivity for each 486 
sample pair (n=34 pairs of samples). The R2 value quoted is a Pearson’s 487 
correlation coefficient.  488 
(G) Proportion of hepatocytes that are multinucleated in samples analysed here, 489 
estimated by counting 500 cells in each H&E section (n=14 patients). Each point 490 
represents the proportion of a patient in the study. The horizontal bars 491 
represent the mean for that aetiological group. 492 
 493 
Extended Figure 2: Copy number and structural variants in chronic liver 494 
disease. (A, B) Genome-wide copy number profiles for two samples. Black 495 
points represent read-depth of discrete windows along the chromosome, 496 
corrected to show overall copy number. Arm-level and whole chromosome gains 497 
and losses are evident. 498 
(C-H) Focal copy number changes and structural variants. Black points represent 499 
read-depth of discrete windows along the chromosome, corrected to show 500 
overall copy number. Lines and arcs represent individual structural variants, 501 
coloured by the orientation of the joined ends (purple, tail-to-tail inverted; 502 
orange, head-to-head inverted; pale blue, tandem duplication-type orientation; 503 
pale green, deletion-type orientation). Events affecting known HCC genes are 504 
marked with labelled arrows (panels C, E, F). 505 
 506 
Extended Figure 3: Events affecting known HCC genes in cohort.  507 
(A) Distribution of somatic point mutations in individual microdissections (x 508 
axis) affecting known HCC genes (y axis). The inset to the left shows the 509 
frequency of events in individual genes. The inset to the bottom shows the 510 
aetiology attributed to the sample, and whether the sample was drawn from 511 
non-cancerous hepatocytes (left) or HCC (right). 512 
(B) Genomic position of single nucleotide substitutions (SNVs; light blue strip, 513 
top) and insertion-deletions (INDELs; dark blue strip, bottom) detected in ALB, 514 
the gene encoding albumin.  515 
 (C) Relationship of gene expression in liver tissue (x axis) and proportion of 516 
indels as a fraction of all point mutations (y axis). The grey line represents a 517 
Poisson regression model with a significant (two-sided likelihood ratio test; p < 518 
10-16) coefficient for gene expression as a predictor for the ratio of indels 519 
(n=5458 genes included in model). The grey ribbon represents the 99% 520 
confidence interval of the parameter estimates. 521 
 522 
Extended Figure 4: Phylogenetic reconstruction of hepatocyte clones in 523 
non-cirrhotic liver samples. 524 
Left column: Heatmap representing the clustering of the variants observed in 525 
each microdissection sample (x-axis) of the non-cirrhotic livers. Each cluster (y-526 
axis) contains mutations for which variant allele fractions across samples are 527 
very similar. The colour scale of the boxes represents the estimated mean variant 528 
allele fraction for that cluster in that sample. 529 
Middle column: Phylogenetic trees constructed from the clustering information. 530 
Solid lines: nesting is in accordance with the pigeon-hole principle. Dashed lines: 531 
nesting is in accordance with the pigeon-hole principle assuming the pool of 532 
hepatocytes to be 70% of cells. Dotted lines: nesting is only based on clustering, 533 
assigning a clone as nested if its constituent LCMs are a subset of LCMs in the 534 
parental clone. Details given in Supplementary Methods. 535 
Right column: Representation of clones according to the physical coordinates of 536 
the LCM samples, overlaid onto H&E stained sections (top), with Masson’s 537 
trichrome and Oil Red-O sections also shown (bottom). Locations of 538 
immune/inflammatory cell infiltrates are marked with yellow rings. Sample sizes 539 
were for PD36713, n=30 microdissections; PD36714, n=35 microdissections; 540 
PD36715, n=26 microdissections; PD36717, n=42 microdissections; PD36718, 541 
n=32 microdissections. 542 
 543 
Extended Figure 5: Phylogenetic reconstruction of hepatocyte clones in 544 
alcohol-related cirrhosis. 545 
Analogous to Extended Figure 4, representing the cirrhotic livers of donors 546 
PD37105, PD37107, PD37110 and PD37111. The pictures in the right column 547 
are of H&E stains on the top, with Masson’s trichrome and a macroscopic 548 
photograph of the liver on the bottom, with HCCs indicated by arrows. Locations 549 
of immune/inflammatory cell infiltrates are marked with yellow rings. Sample 550 
sizes were for PD37105, n=31 microdissections; PD37107, n=41 551 
microdissections; PD37110, n=22 microdissections; PD37111, n=39 552 
microdissections. 553 
 554 
Extended Figure 6: Phylogenetic reconstruction of hepatocyte clones in 555 
non-alcoholic fatty liver disease with cirrhosis. 556 
Analogous to Extended Figure 4, representing the cirrhotic livers of donors 557 
PD37113, PD37114, PD37115, PD37116 and PD37118. The pictures in the right 558 
column are of H&E stains on the top, with Masson’s trichrome and a macroscopic 559 
photograph of the liver on the bottom, with HCCs indicated by arrows. Locations 560 
of immune/inflammatory cell infiltrates are marked with yellow rings. Sample 561 
sizes were for PD37113, n=37 microdissections; PD37114, n=41 562 
microdissections; PD37115, n=34 microdissections; PD37116, n=43 563 
microdissections; PD37118, n=26 microdissections. 564 
 565 
Extended Figure 7: Mutation spectrum of individual microdissections 566 
From each donor, we chose 5 clones to represented the heterogeneity in 567 
trinucleotide context mutation spectra. The six substitution types are shown in 568 
the panel across the top of each clone’s data. Within each panel, the contribution 569 
from the trinucleotide context (bases immediately 5’ and 3’ of the mutated base) 570 
are shown. 571 
 572 
Extended Figure 8: Details of mutational signature extractions 573 
(A) Dot plots showing the concordance for signature attributions between the 574 
two signature algorithms (n=479 microdissections). Mutational signatures on 575 
the y axis were extracted using non-negative matrix factorisation and on the x 576 
axis using a Bayesian hierarchical Dirichlet process. Quoted R values are 577 
Pearson’s correlation coefficients. 578 
(B) Signatures extracted by non-negative matrix factorisation. The six 579 
substitution types are shown in the panel across the top of each clone’s data. 580 
Within each panel, the contribution from the trinucleotide context (bases 581 
immediately 5’ and 3’ of the mutated base) are shown. 582 
(C) Signatures extracted by the Bayesian hierarchical Dirichlet process, as for 583 
panel B. Where a signature matches one from panel B, it is shown on the same 584 
row. 585 
 586 
Extended Figure 9: Transcription strand bias in mutational patterns 587 
(A) Transcription strand bias of T>C mutations at A[T]D context before and after 588 
transcription start sites of highly expressed liver genes.   589 
(B) Bar plots representing the numbers of C>A variants on the transcribed and 590 
non-transcribed strand. Each hepatocyte clone is represented individually (x-591 
axis). Note the strand bias in the highly mutated clones of PD37111, where the 592 
tobacco signature is most active – the strand bias indicates the damaged base is 593 
the guanine, as expected for polycyclic aromatic hydrocarbons. 594 
(C) Bar plots representing the numbers of T>A variants on the transcribed and 595 
non-transcribed strand. Each hepatocyte clone is represented individually (x-596 
axis). Note the strand bias in the highly mutated clones of PD37107, where the 597 
aristolochic acid signature is most active – the strand bias indicates the damaged 598 
base is the adenine, as expected for polycyclic aromatic hydrocarbons. 599 
 600 
Extended Figure 10: Mutations in a B lymphocyte clone in a cirrhotic liver 601 
(A) Illustration of a portion of the B-cell receptor (IGH) region on chromosome 602 
14. Shown are the coverage tracks of an LCM sample that does not belong to the 603 
lymphocyte lineage (top) and a sample that belongs to the lymphocyte lineage 604 
(middle). In the center of the displayed region there is a drop of copy number in 605 
the lymphocyte track, indicating a structural rearrangement. The bottom track 606 
shows the paired-end reads that contribute to a rearrangement event in the 607 
lymphocyte sample, co-localised with the drop in copy number. 608 
(B) Application of the pigeonhole principle – if two clusters of heterozygous 609 
mutations in regions of diploid copy number are in different cells, then their 610 
median variant allele fractions must sum to ≤0.5 (if they sum to >0.5, equivalent 611 
to a combined cellular fraction of >1, there must be some cells that carry both 612 
sets of mutations – hence one cluster would have a subclonal relationship with 613 
the other). Cluster 10 is the cluster with the unique VDJ rearrangement of IGH 614 
shown in panel A and the large number of mutations attributed to signature 9. 615 
Clearly, samples from clusters 2, 11 and 55 etc have VAFs which, when combined 616 
with cluster 10, sum to >0.5. Therefore, they must be subclonal to cluster 10, 617 
even though they do show signature 9. 618 
(C-H) Representative pairwise decision graphs for clusters of mutations. Median 619 
cellular fraction is shown for pairs of clusters across every sample from the 620 
patient. Where at least one sample falls above / to the right of the x+y=1 diagonal 621 
line, those two clusters must share a nested clonal-subclonal relationship.     622 
  623 
Methods 624 
 625 
SAMPLES AND SEQUENCING 626 
Samples 627 
Patients recruited at Addenbrooke’s Hospital, Cambridge gave written informed 628 
consent with approval of the Local Research Ethics Committee (16/NI/0196). 629 
 630 
Normal liver samples were obtained from patients with liver metastases from 631 
colorectal carcinoma (CRC). The liver specimens were obtained from resected 632 
liver distal to the metastases, that were confirmed on histology. None of the 633 
patients had undergone neo-adjuvant systemic therapy; one patient had 634 
undergone pre-operative portal vein embolisation (PD36718) to the ipsilateral 635 
liver lobe. Liver tissue from patients with chronic liver disease (CLD) was 636 
derived from explanted diseased livers at the time of transplantation. All of the 637 
patients were identified as having ARLD or NAFLD by clinical history to the 638 
transplant hepatology and addiction psychiatry teams, as well as explanted liver 639 
histology. None of the patients had undergone trans-arterial chemo-embolisation 640 
(TACE) or other locoregional therapy on the transplant waiting list, except 641 
PD37118 who underwent a single treatment to their HCC with TACE. All of the 642 
CLD patients, except one (PD37105), demonstrated significant pre-operative 643 
impairment of liver function as evidenced by a UKELD of >50. 644 
 645 
The explant liver histology was reviewed by a specialist liver histopathologist 646 
(SED), blinded to the sequencing results. The normal liver specimens had no 647 
fibrosis and no evidence of chronic liver disease; the explanted diseased livers 648 
uniformly demonstrated cirrhosis and HCC. The background liver histology was 649 
scored according to the Kleiner system31 on FFPE samples away from the HCC 650 
and the fresh frozen block used for the sequencing analysis. The Kleiner score 651 
assesses the presence of steatosis, lobular inflammation and hepatocyte 652 
ballooning to generate a cumulative NAS score. The presence or absence of 653 
cellular or nodular dysplasia was globally assessed in clinical FFPE samples 654 
(Supplementary table 1), as well as specifically assessed in the fresh-frozen block 655 
used for the laser capture microdissection and sequencing (Supplementary table 656 
1). Serial H&E-stained sections from the frozen block did not demonstrate 657 
dysplasia in any of the cases (Supplementary table 1). Further, there was no 658 
evidence of CRC or HCC on histological review of the fresh-frozen block used for 659 
sequencing. 660 
 661 
All tissue samples were snap-frozen in liquid nitrogen and stored at -80C in the 662 
Human Research Tissue Bank of the Cambridge University Hospitals NHS 663 
Foundation Trust. 664 
 665 
Preparation of tissue sections 666 
Tissue biopsies were embedded in Optimal Cooling Temperature (OCT, 667 
ThermoFisher) medium at -25C. Sections were cut at a thickness of 20µm using 668 
a Leica Cryotome and transferred onto PEN membrane slides (ThermoFisher). 669 
For fixation, slides were treated with 70% ethanol at room-temperature for 670 
2min. Slides were washed twice in 10% phosphate buffered saline (PBS) at 671 
room-temperature for 10s. For staining, slides were incubated in haematoxylin 672 
for 10s and rinsed twice in water. Slides were then incubated in eosin for 5s and 673 
rinsed once in water. Slides were washed twice with 70% ethanol for 5s, twice 674 
with 100% ethanol for 5s, and in xylene for 5s. Storage was at -20C. Additional 675 
sections were stained for H&E, Masson’s Trichrome and Oil Red O by standard 676 
laboratory techniques. All slides were scanned on a Leica AT2 at ×20 677 
magnification and a resolution of 0.5μm per pixel. 678 
 679 
Laser Capture Microdissection (LCM) 680 
Microdissection was performed using a LCM (Leica Microsystems LMD 7000). 681 
For each biopsy, 48 microdissections were cut with a target size of 20,000µm2, 682 
corresponding to about 400 hepatocyte cells. Images were taken before and after 683 
LCM. 684 
 685 
Sample lysis and DNA preparation 686 
LCM biopsies were lysed using the Arcturus PicoPure DNA Extraction Kit 687 
(ThermoFisher) following the manufacturer’s instructions. DNA libraries for 688 
Illumina sequencing were prepared using a protocol optimized for low input 689 
amounts of DNA, as described32.  690 
 691 
Whole-genome sequencing 692 
Paired-end sequencing reads (150bp) were generated using the Illumina X10 693 
platform for 400 samples, resulting in a target coverage of 30x-70x per sample. 694 
To avoid the known index-hopping artefact, we chose to avoid multiplexing 695 
samples and instead sequenced one sample per flow cell lane. To increase 696 
coverage for a subset of 96 samples, we used multiplexing and achieved 70x 697 
coverage. In addition to the LCM samples we also sequenced a bulk sample for 698 
each biopsy and (where available) associated hepatocellular carcinoma (HCC). 699 
 700 
The healthy liver samples came from wide resections of hepatic metastases of 701 
colorectal cancer. In each case, we sequenced the metastasis – this did not reveal 702 
any mutations shared between the colorectal cancer and liver, nor any variants 703 
shared by all liver samples absent from the colorectal cancer (beyond regions of 704 
loss-of-heterozygosity in the cancer). Likewise, for the cirrhotic liver samples, we 705 
sequenced the matched HCC, not revealing sharing of mutations. In one case, we 706 
sequenced microdissections of the fibrotic tissue, and here also did not find 707 
mutations restricted to all liver cells. 708 
 709 
Sequencing data were mapped to the human genome, GRCh37d5, using the 710 
BWA-Mem algorithm. 711 
 712 
VARIANT CALLING 713 
SNV calling 714 
Substitution variants were called using the Cancer Variants through Expectation 715 
Maximisation (CaVEMan) algorithm33, using the bulk sample of the liver biopsy 716 
as the matched normal. As part of the algorithm, the variants were annotated 717 
using VAGrENT34. Variant calls for bulk sequencing data of the cancer samples 718 
were not further filtered. For sequencing of LCMs, post-filtering was performed 719 
in three steps: 720 
 721 
1. Removal of duplicate counts: we noticed instances where variant bases were 722 
counted twice due to the overlap of paired-end sequencing reads. We removed 723 
such double counting and re-evaluated variant calls after taking double counts 724 
into account. 725 
 726 
2. Removal of variants introduced during library preparation: we noticed the 727 
presence of variants introduced due to incorrect processing of cruciform DNA. 728 
Erroneous variants were often present in inverted repeats and frequently 729 
accompanied by another proximal (~ 1-30bp distance). These inverted repeats 730 
can form cruciform DNA prior to DNA isolation or during library preparation. 731 
The library preparation protocol employed can incorrectly process these 732 
secondary DNA structures and inadvertently introduce one or more erroneous 733 
variants. For every variant the standard deviation (SD) and median absolute 734 
deviation (MAD) of the variant position within the read was separately 735 
calculated for positive and negative strand reads.  736 
In the case that the variant was supported by a low number of reads for a 737 
particular strand, the filtering was based on the statistics determined from the 738 
reads derived from the other strand. It was required that either:  739 
1. ≤  90% of supporting reads report the variant within the first 15% of the 740 
read as calculated from the alignment start. 741 
2. Or, that the MAD > 0 and SD > 4. 742 
 743 
In the case that sufficient reads supporting the variant were available for both 744 
strands it was required for both strands separately that either: 745 
1. ≤  90% of supporting reads report the variant within the first 15% of the 746 
read as calculated from the alignment start. 747 
2. Or, that the MAD > 2 and SD > 2. 748 
3. Or, that at least one strand has fulfills the criteria MAD > 1 and SD > 10. 749 
 750 
3. Comparison with an independent panel: to remove variant calls at badly-751 
mapping sites, we compared variant calls in the sequenced samples of each 752 
donor biopsy with samples from all unrelated donors in our cohort. For each 753 
variant site we expected the reference base to be dominant and conversely 754 
expected badly-mapping sites to contain frequent non-reference base counts. 755 
Thus, we counted the numbers of A, C, G, T, insertion and deletion calls at each 756 
variant site across all unrelated samples, resulting in a large “pileup” table. The 757 
dominance of the reference base was evaluated at each variant site using the 758 
entropy purity metric E: 759 
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where x is the count of base i and the P(xi) are the fractions of base calls. Values 760 
of E close to 0 indicate that almost all reads in the independent panel contain a 761 
single base. Higher values of E indicate a mix of base calls at the site. To identify 762 
an optimal threshold of E for the filtering of variant sites, we evaluated the 763 
entropy metric against a labelled dataset of variant calls. Specifically, during the 764 
clustering of variants using the Bayesian Dirichlet process (described below), we 765 
identified clusters that had variants with low allele frequency present in all 766 
dissections from the same donor. Manual inspection showed that such variants 767 
occurred at badly-mapping sites. Thus, we labelled variant sites in those clusters 768 
as “badly-mapping” and were able to use the Area-Under-the-Receiver-Operator-769 
Curve to identify a threshold value EThr of 0.16 that allowed to separate the two 770 
labelled variant groups with an AUC of 0.99. 771 
 772 
Bayesian Dirichlet process for clustering VAFs across multiple samples 773 
We extend the model previously developed for clustering variant allele fractions 774 
(VAFs) of mutations called in a single sample19 to mutation data across multiple 775 
samples from the same individual. In normal somatic cells, the vast majority of 776 
the genome retains its normal, diploid copy number, which means that we can 777 
cluster the VAFs directly (excluding mutations on the X and Y chromosomes in 778 
males) – this has the considerable advantage that the Dirichlet Process model we 779 
build can rely directly on conjugate prior distributions. The model includes a 780 
potential split-merge step at each cycle of the Gibbs sampler, following a 781 
previously described Metropolis-Hastings proposal for conjugate distributions35. 782 
The algorithm could be extended to include a correction for different copy 783 
number states in given samples for a particular mutation through, for example, a 784 
Metropolis-Hastings update, but at considerable computational cost. The full 785 
mathematical development of the model is detailed in the Supplementary 786 
Methods. 787 
 788 
We ran the Gibbs sampler for 15,000 iterations, dropping the first 10,000 as a 789 
burn-in. We used the ECR algorithm36, implemented in the R package 790 
label.switching, to resolve the label switching problem associated with mixture 791 
models. We dropped clusters containing <100 variant sites.  792 
 793 
Phylogenetic tree construction 794 
Phylogenetic trees were constructed manually using the pigeonhole principle as 795 
described previously19. In short, each cluster identified using the Bayesian 796 
Dirichlet process represented a branch of the phylogenetic tree. Nesting of trees 797 
was identified with three different levels of certainty, illustrated on a pair of 798 
branches A and B: 799 
1. In case the median VAFs of A and B exceeded 100%, the pigeonhole 800 
principle defines that A and B are nested. 801 
2. We can assume that non-hepatocyte cells constitute a sizeable fraction of 802 
each LCM sample. Assuming a non-hepatocyte fraction of 30% we nested 803 
branches when VAFs of A and B exceeded 70%. This non-hepatocyte 804 
fraction was chosen as a conservative estimate of the fraction of cells 805 
intermixed in our microdissections that are not derived from the 806 
hepatocyte clone, based on observed VAF peaks in our data together with 807 
single-cell RNA sequencing data from liver tissue. 808 
3. If identical LCMs are members of both A and B, it is highly likely that A 809 
and B are nested, rather than independent branches. Thus, we also nested 810 
branches where the LCMs in one branch were a subset of the LCMs in the 811 
other (parental) branch. 812 
 813 
In each nesting scenario, we defined the parental branch to be the one with the 814 
higher median VAF in the contained LCMs. We highlighted the evidence level for 815 
nesting in each representation of phylogenetic trees, marking branches with 816 
evidence level 1 with a solid line, level 2 with a dashed line and level 3 with a 817 
dotted line. 818 
 819 
Analysis of driver variants 820 
We curated a list of genes that have been found to be significantly mutated in 821 
liver cancers in a selection of published studies1–4,6,7,37–39, as represented in 822 
Supplementary Table 5. Using the VAGrENT annotations34, we counted any 823 
regulatory, missense, nonsense, frameshift or essential splice variant as a 824 
potential driver variant. To systematically identify genes under mutagenic 825 
selection, we used the dN/dS method17 that screens for genes with an excess of 826 
non-synonymous mutations compared to that expected from the synonymous 827 
mutation rate. 828 
 829 
Sensitivity correction 830 
We identified 138 pairs of LCMs with a midpoint-to-midpoint distance of < 831 
500µm and at least one shared cluster according to the Bayesian Dirichlet 832 
process. These LCMs we assumed to represent the same clone, thus providing an 833 
opportunity to calculate the sensitivity of calling a variant present in one LCM in 834 
the other. If we assume the sensitivity is the same in both samples, then the 835 
maximum likelihood estimate for the sensitivity, when mutations not called in 836 
either sample are unobserved, is given by:  837 
  
   
      
 
where n2 is the number of variants called in both LCMs in each pair and n1 is the 838 
number of variants called only in one of the two LCMs. To evaluate the 839 
relationship of sensitivity with depth-of-coverage and VAF, we performed a 840 
logistic regression of sensitivity against these two predictors using the lm() 841 
function of the R programming language. The model fit was then used to 842 
calculate sensitivity for any LCM sample, given the coverage and VAF of the 843 
sample. 844 
 845 
Mutation burden analysis 846 
We used a linear mixed effects model to fit the number of variants per LCM 847 
sample against each individual’s disease aetiology (normal or cirrhotic) and age. 848 
We defined the individual’s ID as a random effect. The slope of the age coefficient 849 
was allowed to vary with the random effect. To facilitate the analysis, we used 850 
the lmer() function available from the lme4 package of the R programming 851 
language. To determine the significance of the aetiology and age coefficients, we 852 
used ANOVA analysis to perform a 2 test comparing our model with models 853 
omitting the aetiology and age coefficients, respectively.  854 
 855 
Deep targeted sequence validation of mutation calls 856 
For 96 of the microdissections sequenced by whole genome sequencing, we 857 
performed a deep targeted sequencing validation using an Agilent RNA bait-set 858 
covering 350 recurrently mutated cancer genes. Among these genes, a total of 17 859 
mutations were identified in the whole genome sequencing data from the 96 860 
samples – of these, 16 (94%) were validated, at comparable variant allele 861 
fractions, in the targeted deep sequencing data.  862 
 863 
INDEL calling 864 
INDELs were called using cgpPindel40. Variant calls for bulk sequencing data of 865 
the cancer samples were not further filtered. To remove artefactual calls from 866 
the LCM-derived data, we performed two post-filtering steps: 867 
 868 
1) Assignment to SNV-based clusters: we evaluated how well the VAF distribution 869 
of each INDEL across the LCMs from the same donor compared with the VAF 870 
distribution of each SNV-based cluster as identified by the Bayesian Dirichlet 871 
process. Given an INDEL in one LCM sample, we thus counted its occurrence in 872 
all related LCMs and assigned the resulting VAF profile to the SNV clusters’ VAF 873 
profiles using a Bayes’ classifier. We noticed that many INDELs were assigned to 874 
SNV clusters with <100 variants, which we had previously removed from the 875 
SNV analysis. On closer inspection we noticed that those INDELs had low VAF 876 
and occurred frequently in badly-mapping regions. We thus discarded INDELs 877 
assigned to those clusters. 878 
 879 
2) Filtering based on beta-binomial overdispersion parameter: we noticed that 880 
many INDELs occurred with low VAF in a large number of LCMs from the same 881 
donor and were, thus, likely to be artefactual. To systematically identify such 882 
INDELs, we fitted the beta-binomial distribution to the variant counts of each 883 
INDEL across the LCMs from the same donor. Fitted parameter  , the 884 
overdispersion parameter, was used to filter INDEL calls. A high value for 885 
parameter   (overdispersion) occurs when some LCMs have many variant read 886 
counts and others few or none. Conversely, a low value occurs when all LCMs 887 
have a similar number of variant counts (no overdispersion). Based on manual 888 
inspection, we removed variant calls with   < 0.02. 889 
 890 
Copy number calling 891 
CNs were called using the ASCAT algorithm41, assuming an expected ploidy of 4 892 
(to allow for physiologically polyploid hepatocytes) and 60% non-hepatocyte cell 893 
contamination for all samples. Robustness testing around these starting points 894 
(different expected ploidy or purity values) found that the specific values used 895 
did not materially affect the output. Variant calls for bulk sequencing data of the 896 
cancer samples were not further filtered. To remove artefactual variants from 897 
the LCM-derived data, we employed the SNV-based phylogenetic information. 898 
The genome was segmented into 500bp bins and the ASCAT-based copy number 899 
of each bin was calculated. Using the binned CN data we calculated the median 900 
CN in each LCM sample and ASCAT event. For each ASCAT event and LCM sample 901 
we assigned its absolute deviation from the diploid state. We compared each 902 
ASCAT event’s CN profile across the LCM samples with the VAF profile of each 903 
SNV cluster using cosine similarity (described below) to identify the most similar 904 
SNV cluster. Within each SNV cluster we proceeded to merge overlapping ASCAT 905 
events. Using manual inspection, we decided to keep ASCAT events if they 1) had 906 
a cosine similarity of < 0.1 to an SNV cluster and 2) if their assigned SNV cluster 907 
was not removed during SNV analysis due to having < 100 assigned SNVs.  908 
 909 
Structural variant calling 910 
SVs were called using the BRASS algorithm42 911 
(https://github.com/cancerit/BRASS). Variant calls for bulk sequencing data of 912 
the cancer samples were not further filtered. To remove artefactual variants 913 
from the LCM-derived data, we employed post-processing filters. Manual 914 
inspection of the sequencing reads identified for each SV showed that many 915 
reads were identical except for frame-shifts at repetitive sites. We decided that 916 
such reads represented duplicates and designed a filter to systematically remove 917 
these. We removed SVs supported by <2 reads after duplicate removal. Each 918 
remaining SV call was manually inspected.   919 
 920 
Clone size calculation 921 
We determined the midpoint coordinates of each LCM manually from the 922 
microscopy images collected during dissection. For each LCM belonging to a 923 
clone as determined by the Bayesian Dirichlet process, we used the function 924 
chull of the R programming language to identify the coordinates of the convex 925 
hull that included all LCMs. We identified the midpoint of each polygon as the 926 
average coordinate of all convex hull vertices. The size of the clone was then 927 
assigned to be the Euclidean distance between each convex hull vertex and the 928 
polygon’s midpoint. For clones that only consisted of a single LCM, we assigned 929 
the minimum clone size discovered across all clones. 930 
 931 
Extraction of mutational signatures from SNV contexts using HDP 932 
Mutational signatures were extracted using the HDP package 933 
(https://github.com/nicolaroberts/hdp) relying on the hierarchical Bayesian 934 
Dirichlet process. The units of signature extraction were mutations assigned to 935 
individual branches of the phylogenetic tree, grouped per patient, from the LCM 936 
data. In addition, to provide a comparison against signatures extracted in HCCs, 937 
we added catalogues of somatic substitutions from 54 whole genomes sequenced 938 
by the TGCA, analysed using the same core algorithms as used for the LCM data. 939 
The tool was used without defining prior signatures. As hyperparameters we set 940 
alpha and beta to 6 for the alpha clustering parameter. Extraction was started 941 
with 40 data clusters (parameter ‘initcc’). The Gibbs sampler was run with 942 
10,000 burn-in iterations (parameter ‘burnin’). With a spacing of 50 iterations 943 
(parameter ‘space’), 50 iterations were collected (parameter ‘n’). After each 944 
Gibbs sampling iteration, 3  iterations of concentration parameter sampling were 945 
performed (parameter ‘cpiter’). Resulting signatures were compared to 946 
published signatures20,43 using the cosine similarity metric described below. 947 
Extracted signatures with cosine similarity >0.9 compared to a known signature 948 
from either the COSMIC20 or PCAWG43 catalogue of signatures were assigned the 949 
name of the known signature with the highest similarity. Extracted signatures 950 
with cosine similarity <0.9 to any of the known signatures were assigned new 951 
names, indexed with letters A, B, and C. 952 
 953 
Extraction of mutational signatures from SNV contexts using SigProfiler 954 
We used SigProfiler to extract mutational signatures, relying on the non-negative 955 
matrix factorization (NNMF) method44. In particular, we report the “Decomposed 956 
Solution” output by the package.  957 
 958 
Cosine similarity calculation 959 
To compare two vectors A and B, cosine similarity was calculated as follows:  960 
            
∑     
 
   
√∑   
  
   √∑   
  
   
 
 961 
Analysis of INDEL proportion and gene expression 962 
A list of transcribed regions was retrieved from ENSEMBL using the BioMaRt 963 
package45. We identified the subset of INDEL and SNV variants that overlapped 964 
with the transcribed regions. The proportion of INDELs in comparison to the 965 
total number of INDELs and SNVs per gene was calculated. Gene expression was 966 
assigned using the “liver” dataset from the Genotype-Tissue Expression project46. 967 
To test for the relationship of gene expression on INDEL proportion, we fit a 968 
Poisson regression using the glm function of the R programming language. We 969 
modelled the number of INDELs per gene against an offset of the total number of 970 
variants per gene and the gene’s expression.  971 
 972 
Analysis of T>C transcription strand bias at transcription start sites 973 
We performed this analysis analogously to a published approach22. In short, we 974 
retrieved the genomic coordinates of transcription start sites of the all 975 
overexpressed genes in the liver (GTEx46). We tiled the 10 kilobases up- and 976 
downstream of the transcription start site into 1,000bp bins. We overlapped all 977 
T>C (transcribed) and A>G (untranscribed) variant calls with the tiled regions 978 
and summed the number of variants in each tile across all included genes. We 979 
also extracted the number of T and A bases in each tile. To test whether strand 980 
bias was significant only in transcribed regions, we fit a Poisson regression for 981 
the number of variant calls against the following predictors: strand (transcribed 982 
/ untranscribed), distance from TSS (0 for upstream, 1 for downstream), 983 
aetiology (cirrhosis, no cirrhosis) and used the number of T and A bases in each 984 
tile as the offset variable. 985 
 986 
Analysis of C>A and T>A transcription strand bias 987 
We used the MutationalPatterns package47 to assign the transcription state for 988 
each C>A variant. We retrieved the genomic coordinates of all transcribed 989 
regions from ENSEMBL using the BioMaRt package45 and extracted the 990 
frequencies of C and G nucleotides in these regions. To test for significance of 991 
transcription strand bias, we performed a Poisson regression for the number of 992 
C>A variants in each sample and transcription strand against factor variables for 993 
the transcription strand, the patient ID and an interaction term for the two 994 
factors. We used the C, G nucleotide frequency as an offset variable. To test for 995 
significance of transcription strand bias for a given donor, we coded the patient 996 
ID in a binary fashion: “1” for the target donor, “0” otherwise. We proceeded 997 
analogously to test for transcription strand bias of T>A variants, using A and T 998 
nucleotide frequencies as the offset. 999 
 1000 
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